fenofibrate has been researched along with Pregnancy in 23 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Prenatal fenofibrate administration attenuated detrimental effects induced by MIA on both the schizophrenia-like behavioral phenotype and dopamine transmission in male offspring." | 7.91 | The PPARα agonist fenofibrate attenuates disruption of dopamine function in a maternal immune activation rat model of schizophrenia. ( Aroni, S; De Felice, M; Devoto, P; Fanni, S; Frau, R; Melis, M; Muntoni, AL; Pistis, M, 2019) |
| " Valproic acid (VPA) is an anticonvulsant drug in both human and rodents with teratogenic effects during pregnancy." | 7.91 | Benefits of Fenofibrate in prenatal valproic acid-induced autism spectrum disorder related phenotype in rats. ( Mirza, R; Sharma, B, 2019) |
| "To describe a successful pregnancy in a patient who used fenofibrate during the first trimester." | 7.78 | Use of fenofibrate during the first trimester of unplanned pregnancy in a patient with hypertriglyceridemia. ( Aytemir, K; Canpolat, U; Sahiner, L; Sunman, H, 2012) |
| "Fenofibrate was used safely and successfully during pregnancy in this case of hypertriglyceridemia-associated pancreatitis refractory to conservative measures." | 7.77 | Hyperlipidemia-associated pancreatitis in pregnancy managed with fenofibrate. ( Lorenz, RP; Smith, JM; Whitten, AE, 2011) |
| "The social motivational theory of autism spectrum disorder (ASD) focuses on social anhedonia as key causal feature of the impaired peer relationships that characterize ASD patients." | 5.56 | Targeting PPARα in the rat valproic acid model of autism: focus on social motivational impairment and sex-related differences. ( Braccagni, G; De Montis, MG; Gambarana, C; Guzzi, F; Parenti, M; Scheggi, S, 2020) |
| "Bexarotene is a synthetic retinoid from the subclass of retinoids called rexinoids which selectively activate retinoid X receptors." | 5.39 | U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. ( Azurdia, R; Cowan, R; Eagle, M; Gallop-Evans, E; Graham-Brown, R; Illidge, T; Morris, S; Parry, E; Scarisbrick, JJ; Soran, H; Wachsmuth, R; Wain, EM; Whittaker, S; Wierzbicki, AS, 2013) |
| " Prenatal fenofibrate administration attenuated detrimental effects induced by MIA on both the schizophrenia-like behavioral phenotype and dopamine transmission in male offspring." | 3.91 | The PPARα agonist fenofibrate attenuates disruption of dopamine function in a maternal immune activation rat model of schizophrenia. ( Aroni, S; De Felice, M; Devoto, P; Fanni, S; Frau, R; Melis, M; Muntoni, AL; Pistis, M, 2019) |
| " Valproic acid (VPA) is an anticonvulsant drug in both human and rodents with teratogenic effects during pregnancy." | 3.91 | Benefits of Fenofibrate in prenatal valproic acid-induced autism spectrum disorder related phenotype in rats. ( Mirza, R; Sharma, B, 2019) |
| "Fenofibrate was used safely and successfully during pregnancy in this case of hypertriglyceridemia-associated pancreatitis refractory to conservative measures." | 3.77 | Hyperlipidemia-associated pancreatitis in pregnancy managed with fenofibrate. ( Lorenz, RP; Smith, JM; Whitten, AE, 2011) |
| "A fenofibrate was proposed but declined due to our patient's wish to breastfeed." | 1.72 | Hypertriglyceridaemia in pregnancy: an unexpected diagnosis and its management. ( Barclay, K; Kaplan, F; Koysombat, K; Padmagirison, R, 2022) |
| "The social motivational theory of autism spectrum disorder (ASD) focuses on social anhedonia as key causal feature of the impaired peer relationships that characterize ASD patients." | 1.56 | Targeting PPARα in the rat valproic acid model of autism: focus on social motivational impairment and sex-related differences. ( Braccagni, G; De Montis, MG; Gambarana, C; Guzzi, F; Parenti, M; Scheggi, S, 2020) |
| "Bexarotene is a synthetic retinoid from the subclass of retinoids called rexinoids which selectively activate retinoid X receptors." | 1.39 | U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. ( Azurdia, R; Cowan, R; Eagle, M; Gallop-Evans, E; Graham-Brown, R; Illidge, T; Morris, S; Parry, E; Scarisbrick, JJ; Soran, H; Wachsmuth, R; Wain, EM; Whittaker, S; Wierzbicki, AS, 2013) |
| "Fenofibrate treatment did not modify plasma free fatty acid (FFA) concentration in virgin rats, it greatly increased it in pregnant animals." | 1.35 | Fenofibrate reduces adiposity in pregnant and virgin rats but through different mechanisms. ( Bocos, C; Gonzalez, MC; Herrera, E; Vidal, H, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (8.70) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 8 (34.78) | 29.6817 |
| 2010's | 8 (34.78) | 24.3611 |
| 2020's | 4 (17.39) | 2.80 |
| Authors | Studies |
|---|---|
| Singh, S | 1 |
| Dhar, R | 1 |
| Karmakar, S | 1 |
| Barclay, K | 1 |
| Koysombat, K | 1 |
| Padmagirison, R | 1 |
| Kaplan, F | 1 |
| Grady, J | 1 |
| Clifford, C | 1 |
| Treadwell, MC | 1 |
| Parikh, ND | 1 |
| Satishchandran, A | 1 |
| Scheggi, S | 1 |
| Guzzi, F | 1 |
| Braccagni, G | 1 |
| De Montis, MG | 1 |
| Parenti, M | 1 |
| Gambarana, C | 1 |
| Strassburg, CP | 1 |
| De Felice, M | 1 |
| Melis, M | 1 |
| Aroni, S | 1 |
| Muntoni, AL | 1 |
| Fanni, S | 1 |
| Frau, R | 1 |
| Devoto, P | 1 |
| Pistis, M | 1 |
| Mirza, R | 1 |
| Sharma, B | 1 |
| Savas, Ü | 1 |
| Machemer, DEW | 1 |
| Hsu, MH | 1 |
| Gaynor, P | 1 |
| Lasker, JM | 1 |
| Tukey, RH | 1 |
| Johnson, EF | 1 |
| González, MC | 2 |
| Corton, JC | 1 |
| Cattley, RC | 1 |
| Herrera, E | 4 |
| Bocos, C | 4 |
| Vidal, H | 2 |
| Marche, K | 1 |
| Danel, T | 1 |
| Bordet, R | 1 |
| Whitten, AE | 1 |
| Lorenz, RP | 1 |
| Smith, JM | 1 |
| Moustafa, T | 1 |
| Fickert, P | 1 |
| Magnes, C | 1 |
| Guelly, C | 1 |
| Thueringer, A | 1 |
| Frank, S | 1 |
| Kratky, D | 1 |
| Sattler, W | 1 |
| Reicher, H | 1 |
| Sinner, F | 1 |
| Gumhold, J | 1 |
| Silbert, D | 1 |
| Fauler, G | 1 |
| Höfler, G | 1 |
| Lass, A | 1 |
| Zechner, R | 1 |
| Trauner, M | 1 |
| Sunman, H | 1 |
| Canpolat, U | 1 |
| Sahiner, L | 1 |
| Aytemir, K | 1 |
| Scarisbrick, JJ | 1 |
| Morris, S | 1 |
| Azurdia, R | 1 |
| Illidge, T | 1 |
| Parry, E | 1 |
| Graham-Brown, R | 1 |
| Cowan, R | 1 |
| Gallop-Evans, E | 1 |
| Wachsmuth, R | 1 |
| Eagle, M | 1 |
| Wierzbicki, AS | 2 |
| Soran, H | 1 |
| Whittaker, S | 1 |
| Wain, EM | 1 |
| Mikhailidis, DP | 1 |
| Wray, R | 1 |
| Soria, A | 2 |
| González, Mdel C | 1 |
| Vickers, MH | 1 |
| Hofman, PL | 1 |
| Gluckman, PD | 1 |
| Lobie, PE | 1 |
| Cutfield, WS | 1 |
| Blane, GF | 1 |
| Pinaroli, F | 1 |
| Staels, B | 1 |
| Vu-Dac, N | 1 |
| Kosykh, VA | 1 |
| Saladin, R | 1 |
| Fruchart, JC | 1 |
| Dallongeville, J | 1 |
| Auwerx, J | 1 |
| Caroli-Bosc, FX | 1 |
| Le Gall, P | 1 |
| Pugliese, P | 1 |
| Delabre, B | 1 |
| Caroli-Bosc, C | 1 |
| Demarquay, JF | 1 |
| Delmont, JP | 1 |
| Rampal, P | 1 |
| Montet, JC | 1 |
| Ujházy, E | 1 |
| Onderová, E | 1 |
| Horáková, M | 1 |
| Bencová, E | 1 |
| Durisová, M | 1 |
| Nosál, R | 1 |
| Balonová, T | 1 |
| Zeljenková, D | 1 |
2 reviews available for fenofibrate and Pregnancy
| Article | Year |
|---|---|
[Modern treatment of primary biliary cholangitis].
Topics: Bezafibrate; Budesonide; Chenodeoxycholic Acid; Cohort Studies; Female; Fenofibrate; Humans; Liver C | 2018 |
Drug treatment of combined hyperlipidemia.
Topics: Acute Disease; Clofibric Acid; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hydroxymethyl | 2001 |
21 other studies available for fenofibrate and Pregnancy
| Article | Year |
|---|---|
Fenofibrate mediated activation of PPARα negatively regulates trophoblast invasion.
Topics: Cell Movement; Female; Fenofibrate; Humans; Ligands; Placenta; PPAR alpha; Pregnancy; Trophoblasts | 2022 |
Hypertriglyceridaemia in pregnancy: an unexpected diagnosis and its management.
Topics: Diet, Fat-Restricted; Female; Fenofibrate; Humans; Hyperlipidemias; Hypertriglyceridemia; Pregnancy | 2022 |
Use of fenofibrate for intrahepatic cholestasis of pregnancy.
Topics: Cholestasis, Intrahepatic; Female; Fenofibrate; Humans; Pregnancy; Pregnancy Complications | 2023 |
Targeting PPARα in the rat valproic acid model of autism: focus on social motivational impairment and sex-related differences.
Topics: Animals; Anxiety; Autistic Disorder; Behavior, Animal; Biomarkers; Disease Models, Animal; Female; F | 2020 |
The PPARα agonist fenofibrate attenuates disruption of dopamine function in a maternal immune activation rat model of schizophrenia.
Topics: Animals; Disease Models, Animal; Dopamine; Female; Fenofibrate; Male; Neuroimmunomodulation; Neurons | 2019 |
Benefits of Fenofibrate in prenatal valproic acid-induced autism spectrum disorder related phenotype in rats.
Topics: Animals; Anticonvulsants; Anxiety; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Br | 2019 |
Opposing roles of peroxisome proliferator-activated receptor alpha and growth hormone in the regulation of CYP4A11 expression in a transgenic mouse model.
Topics: Animals; Clofibric Acid; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme System; Fasting; Female; Fe | 2009 |
Peroxisome proliferator-activated receptor alpha (PPARalpha) agonists down-regulate alpha2-macroglobulin expression by a PPARalpha-dependent mechanism.
Topics: alpha-Macroglobulins; Animals; Down-Regulation; Female; Fenofibrate; Male; Mice; PPAR alpha; Pregnan | 2009 |
Fenofibrate reduces adiposity in pregnant and virgin rats but through different mechanisms.
Topics: Adipocytes; Adipose Tissue, White; Adiposity; Animals; Biomarkers; Fatty Acids; Female; Fenofibrate; | 2009 |
Fetal alcohol-induced hyperactivity is reversed by treatment with the PPARα agonist fenofibrate in a rat model.
Topics: Animals; Disease Models, Animal; Female; Fenofibrate; Fetal Alcohol Spectrum Disorders; Hyperkinesis | 2011 |
Hyperlipidemia-associated pancreatitis in pregnancy managed with fenofibrate.
Topics: Adult; Blood Glucose; Female; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Infan | 2011 |
Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; | 2012 |
Use of fenofibrate during the first trimester of unplanned pregnancy in a patient with hypertriglyceridemia.
Topics: Adult; Female; Fenofibrate; Fetal Development; Humans; Hypertriglyceridemia; Hypolipidemic Agents; I | 2012 |
U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.
Topics: Adult; Amylases; Anticarcinogenic Agents; Bexarotene; Blood Cell Count; Blood Glucose; Cholesterol, | 2013 |
Triglyceridemia and peroxisome proliferator-activated receptor-alpha expression are not connected in fenofibrate-treated pregnant rats.
Topics: Acyl-CoA Oxidase; Animals; Carnitine O-Palmitoyltransferase; Female; Fenofibrate; Gene Expression; H | 2005 |
Combination therapy with acipimox enhances the effect of growth hormone treatment on linear body growth in the normal and small-for-gestational-age rat.
Topics: Animals; Birth Weight; Blood Pressure; Bone Development; Fatty Acids, Nonesterified; Female; Fenofib | 2006 |
[Fenofibrate: animal toxicology in relation to side-effects in man (author's transl)].
Topics: Abnormalities, Drug-Induced; Animals; Biopsy; Clofibrate; Cricetinae; Dogs; Female; Fenofibrate; Hum | 1980 |
Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates.
Topics: Acyl-CoA Oxidase; Aging; Animals; Apolipoprotein C-III; Apolipoproteins C; Base Sequence; Cells, Cul | 1995 |
Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population.
Topics: Anticholesteremic Agents; Cholelithiasis; Double-Blind Method; Female; Fenofibrate; Humans; Hydroxym | 2001 |
Opposite metabolic response to fenofibrate treatment in pregnant and virgin rats.
Topics: Adipose Tissue; Animals; Cholesterol; Cholesterol, VLDL; Female; Fenofibrate; Fetus; Hypolipidemic A | 2002 |
Teratological study of the hypolipidaemic drugs etofylline clofibrate (VULM) and fenofibrate in Swiss mice.
Topics: Animals; Body Weight; Clofibrate; Female; Fenofibrate; Fetus; Gestational Age; Hypolipidemic Agents; | 1989 |